New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials

Table 1 Data description: summary of patient characteristics from the ADNI and the clinical trials of the CAMD and ADCS cohorts

Study	Sample size	Gender (% Females)	APOE (% ε4 positive)	ADAS-Cog^a	Study duration
ADNI	1275	41.7	58.7	14.2 ± 8.5	8 years
CAMD-1105	325	51.0	-	25.2 ± 12.2	20 months
CAMD-1131	57	59.6	-	20.5 ± 3.6	24 weeks
CAMD-1132	412	43.4	38.0	19.1 ± 3.1	51 weeks
CAMD-1140	137	42.3	-	19.1 ± 3.4	24 weeks
CAMD-1141	492	55.3	-	9.9 ± 6.0	23 months
CAMD-1142	405	56.0	64.1	25.3 ± 10.4	18 months
ADCS-HU [18]	210	64.4	65.2	27.1 ± 10.8	24 months
ADCS-DHA [19]	402	52.5	57.7	23.9 ± 9.0	18 months
ADCS-VN [20]	300	63.1	71.3	30.1 ± 9.8	24 months
ADCS-HC [21]	409	53.9	70.0	22.6 ± 8.6	18 months
ADCS-LL [22]	406	59.9	55.3	23.9 ± 10.5	18 months
ADCS-MCI [67]	769	47.0	53.0	11.03 ± 4.2	26 months

ADNI Alzheimer’s Disease Neuroimaging Initiative, CAMD Coalition against Major Diseases, ADCS Alzheimer’s Disease Cooperative Study, APOE apolipoprotein-E, HU Huperzine, DHA Docosahexaenoic Acid, VN Valproate Neuroprotection, HC Homocysteine, LL Simvastatin, MCI Mild Cognitive Impairment
^aSummary total ADAS-Cog scores are represented as mean ± standard deviation

ISSN: 1758-9193